Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The sFIDA assay demonstrates high sensitivity (down to femtomolar range) and specificity for detecting protein oligomers in plasma. For example, quantification of Aβ oligomers in plasma samples revealed lower concentrations in patients with subjective cognitive decline and Alzheimer’s disease compared to healthy controls. Correlation analysis between CSF and plasma suggests impaired clearance dependent on ApoE ε4 status.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Attyloid.